REG - Oxford Biomedica PLC - Board Changes

Oxford BioMedicaAnnouncement

11/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240311:nRSK2473Ga&default-theme=true

RNS Number : 2473G  Oxford Biomedica PLC  11 March 2024

 

 

Board changes following transformation to pure-play CDMO business model

Oxford, UK - 11 March 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and
gene therapy CDMO, today announces that CDMO expert, Peter Soelkner, will join
the Board as a Non-Executive Director, effective from 15 March 2024.
Concurrently, as part of Oxford Biomedica's transformation into a pure-play
CDMO, the Company announces that Catherine Moukheibir and Dr. Michael Hayden
have informed the Board that they do not intend to stand for re-election at
the upcoming Annual General Meeting in June 2024. Dr. Michael Hayden will
continue to be an adviser to the Science and Technology Advisory Committee.

 

Peter Soelkner has more than 30 years' experience in the global pharmaceutical
services industry with significant CDMO expertise. He is currently Managing
Director of Vetter Pharma, a global Aseptic Filling and Packaging CDMO, where
over the past 15 years he has helped grow revenues from $200 million to more
than $1 billion. Prior to Vetter, Mr. Soelkner held various senior positions
at Sartorius including Vice President of the Americas region where he expanded
the global footprint of the business across the US and multiple sectors. He
has an MBA from Columbia Business School, New York and Masters in Chemical
Engineering from TU Dortmund University, Germany.

 

Dr. Roch Doliveux, Non-Executive Chairman of Oxford Biomedica, commented:
"Alongside OXB's transformation to become a pure-play viral vector CDMO, the
Board of Directors has reviewed its breadth of skills and taken the decision
to streamline the Board whilst bolstering its CDMO expertise. In light of
this, we are delighted to welcome Peter Soelkner given his impressive track
record in significantly growing Vetter, a leading global CDMO from $200m to
more than $1bn in revenues. In parallel, Catherine Moukheibir and Dr. Michael
Hayden, who have played a defining role in shaping OXB's new strategy, both
volunteered not to stand for re-election at the next AGM given that their
strengths lie more in therapeutics rather than CDMO. I would like to
personally thank Catherine and Michael for their impeccable service, loyalty
and valuable insights."

 

Peter Soelkner commented: "I am pleased to be joining this innovative,
client-centric, global business at such an exciting juncture in the Company's
journey. In my view Oxford Biomedica is extremely well-positioned as a
pure-play CDMO and I am excited to apply my skillset and experience to help
deliver the strategy to clients, enabling them to deliver life-changing
therapies to patients."

 

Relevant disclosures

 

There are no disclosures required to be made in accordance with LR 9.6.13R.

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

 

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 1865 509 737 / E:
ir@oxb.com

 

ICR Consilium:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy contract development and manufacturing organisation (CDMO) with a
mission to enable its clients to deliver life changing therapies to patients
around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV), adenoviral vectors, and other viral vector types. Oxford
Biomedica's world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near
Boston, MA, US. Learn more at www.oxb.com (https://www.oxb.com/) , and follow
us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/) and
YouTube (https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFVTVRIILIS